

## Special Issue

# *Bordetella pertussis* Infection and Vaccination

### Message from the Guest Editor

Pertussis or whooping cough is an acute infection of the respiratory tract caused by the bacterium *Bordetella pertussis* (Bp). Despite good vaccination coverage, it remains a disease with one of the highest residual morbidity and mortality, and it is especially dangerous for infants and young children. At present, not only is the number of pertussis cases increasing, but the Bp carriership in the human population also remains high. Several attempts have been made to improve current vaccination strategies, such as optimizing the composition of current acellular vaccines or testing alternative vaccination routes. This Special Issue of *Vaccines* focuses on research that aims to understand immune responses to Bp infection and vaccination, which can shed light on the high pertussis incidence and provide strategies for better pertussis management at the population level. Submissions to this Special Issue can be studies that either evaluate current pertussis vaccines or are aiming to improve them. Research in both human and animal models are welcome. Dr. Magdalena A. Berkowska

---

### Guest Editor

Dr. Magdalena A. Berkowska

Department of Immunology, Leiden University Medical Centre (LUMC),  
2333 ZA Leiden, The Netherlands

---

### Deadline for manuscript submissions

closed (31 October 2022)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/71960](https://mdpi.com/si/71960)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).